Tetracycline is not outdated. Its original 1950s formula is prescribed far less than it used to be, but the tetracycline family as a whole, led by doxycycline, is still a first-choice treatment for acne, Lyme disease, Rocky Mountain spotted fever, and malaria prevention in travellers. In 2024 the CDC added a brand new role for it too, as after-sex prevention against certain bacterial infections. And three completely new tetracycline-class antibiotics reached the market as recently as 2018. This is not a retired drug family. It quietly reinvented itself.

Patients frequently ask me whether tetracycline is even still a real medicine, and my answer is always the same: you are almost certainly still taking it, you are just taking it under a different name. The confusion is understandable. The specific molecule called tetracycline has genuinely fallen out of favour. But the class it belongs to has not gone anywhere. It has grown.

Is Tetracycline Still Used Today?

Here is what most patients do not realise about their prescription. When a doctor prescribes doxycycline, minocycline, or sarecycline, they are prescribing a member of the tetracycline class, the same broad family that gave the group its name back in the 1950s.[1] Original tetracycline is prescribed rarely now, mostly because doxycycline does the same job with fewer daily doses and a gentler side-effect profile. But narrow that lens too far and you miss the bigger picture. As a class, tetracyclines remain some of the most widely used antibiotics in the world.

Doxycycline alone sits on most national essential medicines lists. It treats infections that other antibiotic classes cannot reach as effectively, and for a handful of conditions, nothing else comes close. That is not the profile of a retired drug.

Where Tetracycline's Family Is Still the Preferred Treatment

The clearest way to answer whether this drug family is outdated is to look at what it is actually being used for right now, in real prescribing guidelines, not textbooks from decades ago.

That last one surprises most people. In 2024, the CDC finalised guidance recommending a single 200 mg dose of doxycycline, taken within 72 hours of sex, to reduce the risk of syphilis, chlamydia, and gonorrhoea in specific high-risk groups.[3] Trial data behind that recommendation showed reductions of more than 70 percent for syphilis and chlamydia, and roughly 50 percent for gonorrhoea. That is not the kind of guidance regulators write for a drug on its way out. It is the kind written for a drug proving useful in an entirely new way.

Why So Many People Assume It Has Been Phased Out

The confusion mostly comes down to naming. Original tetracycline required three or four doses a day, absorbed poorly with food or dairy, and carried a stronger tooth-staining risk than its descendants. Doxycycline solved most of those problems: once or twice daily dosing, more reliable absorption, and a meaningfully lower affinity for binding calcium in developing bone and teeth.[4] Prescribers switched. Patients kept taking a tetracycline-class drug. They just stopped hearing the word "tetracycline" on the label.

But naming is not the only reason. Some genuine resistance did develop against first-generation tetracycline over seventy years of use, and that resistance is real and worth understanding. It just does not tell the whole story on its own.

Tetracycline Resistance: How Real Is the Problem?

Bacteria resist tetracyclines mainly through two mechanisms: efflux pumps that physically push the drug back out of the cell before it can act, and ribosomal protection proteins that shield the bacterial machinery the drug is designed to block.[5] Decades of widespread use, in humans and in livestock, gave resistant strains room to spread. For some infections, older tetracycline genuinely is not the reliable choice it once was.

I often see this misunderstood at the counter as proof the whole drug class has failed. It has not. Doxycycline retains strong activity against the organisms it is actually prescribed for today, precisely because prescribers have narrowed its use toward the infections where resistance is not the deciding factor: rickettsial diseases, Lyme disease, malaria prophylaxis, acne. And where resistance genuinely was becoming a problem, the pharmaceutical industry did not walk away from the class. It engineered around the resistance instead.

That same reasoning applies directly to tetracyclines. Doxycycline is a broad-spectrum antibiotic, which is exactly why it works so well as an empirical choice for tick-borne illness before lab confirmation comes back. Used carelessly for infections that do not need that breadth, it contributes to the same resistance pressure any broad-spectrum drug does. Used deliberately, for the infections where it remains the right tool, it is nowhere close to obsolete.

The Tetracycline Class Just Got Three New Members

If tetracyclines were truly a dying antibiotic class, drug developers would have stopped investing in them decades ago. The opposite happened. In 2018, the FDA approved three new tetracycline-class antibiotics in a single year: eravacycline, omadacycline, and sarecycline.[6] Each one was specifically engineered to dodge the resistance mechanisms that limit older tetracyclines, and each targets a different clinical gap.

Eravacycline treats complicated intra-abdominal infections, including those caused by multidrug-resistant organisms. Omadacycline covers community-acquired pneumonia and serious skin infections. Sarecycline was designed specifically for acne, with a narrower spectrum than doxycycline that spares more of the patient's normal gut bacteria during long acne courses. None of these exist to replace a drug nobody uses anymore. They exist because the underlying chemistry still has clinical value worth building on.

The Two Real Safety Rules Behind Tetracycline's Old-Fashioned Reputation

Two long-standing warnings do explain some of the "outdated" reputation, and both are worth understanding rather than dismissing.

The first is tooth staining. Tetracyclines bind to calcium in developing teeth and bone, and if given during tooth development, they can cause permanent yellow, grey, or brown discolouration.[7] For decades this meant an outright ban under age 8. That guidance has softened with better evidence. Doxycycline binds calcium far less aggressively than original tetracycline, and the American Academy of Pediatrics now recommends short doxycycline courses for children of any age when treating Rocky Mountain spotted fever, because the risk of untreated infection is greater than the dental risk of a brief course.[2] That single dosing decision reflects exactly how much this drug family has moved on from its 1970s reputation.

The second rule is sun sensitivity. Tetracyclines, doxycycline especially, can trigger a fast, severe sunburn-like reaction on any skin exposed to UV light while you are on the course. This is a well-documented, manageable side effect, not a reason to avoid the drug altogether. Our guide on why some antibiotics make you avoid sunlight walks through exactly how to protect yourself while still finishing your course.

That same weight-conscious, benefit-versus-risk thinking is exactly what protects the youngest patients on any antibiotic. Our piece on gentamicin safety in newborns covers a different antibiotic entirely, but the underlying principle is identical: a drug with real, documented risks is not automatically the wrong choice once dosing and monitoring are done properly.

Tetracycline Myths vs Facts

Questions Patients Ask Me Most

For the wider picture of how every antibiotic class fits into safe, responsible use, our complete guide to antibiotics, uses, misuse, and resistance covers the principles behind every decision discussed here.

Commonly Searched Topics

Related Guides

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Tetracycline-class antibiotics are prescription medicines. Always consult your pharmacist or doctor before starting, stopping, or changing any antibiotic, especially for pregnant women, breastfeeding mothers, and children under 8.

References

1. Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17-32. pubmed.ncbi.nlm.nih.gov
2. American Academy of Pediatrics Red Book guidance on doxycycline use for Rocky Mountain spotted fever in children, cited via Stultz JS, Eiland LS. Doxycycline and tooth discoloration in children. Ann Pharmacother. 2019;53(11):1162-1166. pubmed.ncbi.nlm.nih.gov
3. Bachmann LH, et al. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recomm Rep. 2024;73:1-8. cdc.gov
4. Cross R, Ling C, Day NPJ, McGready R, Paris D. Revisiting doxycycline in pregnancy and early childhood, time to rebuild its reputation? Expert Opin Drug Saf. 2016;15(3):367-382. pubmed.ncbi.nlm.nih.gov
5. Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med. 2016;6(4):a025387. ncbi.nlm.nih.gov
6. Kaewpoowat Q, et al. Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Ann Med. 2022;54(1):1516-1526. ncbi.nlm.nih.gov
7. Sanchez AR, Rogers RS, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004;43(10):709-715. pmc.ncbi.nlm.nih.gov